Table 2 Efficacy measures at week 5.

From: Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT trials

 

Xanomeline/Trospium (n = 314)

Placebo (n = 326)

Difference (95% CI)

Cohen’s d

p value

Primary endpoint

     

 PANSS total score

–19.4 (1.0)

–9.6 (1.0)

−9.9 (–12.4, –7.3)

0.65

<0.0001

Secondary outcome measures

     

 PANSS positive subscale score

–6.3 (0.3)

–3.1 (0.3)

–3.2 (–4.1, –2.4)

0.67

<0.0001

 PANSS negative subscale score

–3.0 (0.3)

–1.3 (0.3)

–1.7 (–2.4, –1.0)

0.40

<0.0001

 PANSS Marder negative factor score

–3.8 (0.3)

–1.8 (0.3)

–2.0 (–2.8, –1.2)

0.42

<0.0001

 CGI-S scale score

–1.1 (0.1)

–0.5 (0.1)

–0.6 (–0.8, –0.4)

0.63

<0.0001

 PANSS respondersa (≥30% reduction from baseline in PANSS total score)

130/314 (41.4%)

68/326 (20.9%)

20.5 (13.4 to 27.4)

NA

<0.0001

  1. Data are LSM change (SE) from baseline or n/N%.
  2. aFloor-adjusted total score (total score minus 30); last observation carried forward. Assessed in participants with available week 5 scores.
  3. CGI-S Clinical Global Impression–Severity, LSM least squares mean, SE standard error, PANSS Positive and Negative Syndrome Scale.
Back to article page